Skip to Main Content

Adil I. Daud


Oncologist and melanoma specialist
Immunotherapy researcher, history and literature buff

Dr. Adil Daud, an oncologist, specializes in melanoma and other skin cancers. He is co-director of the Melanoma Center. In addition to caring for patients, he directs research to better understand the biology of melanoma and to develop new treatments. He has developed and led many clinical trials that have expanded the use of gene therapy for melanoma.

Daud earned a medical degree at the Government Medical College, Nagpur. He completed both an internship and a residency in internal medicine at Indiana University School of Medicine, followed by a fellowship in hematology-oncology at Memorial Sloan Kettering Cancer Center. Prior to joining UCSF Medical Center, he was a researcher at the Moffitt Cancer Center in Tampa, Florida, for seven years.

Daud has won numerous awards, including a Young Investigator Award from the American Society of Clinical Oncology and selection as a Castle Connolly Top Doctor.

  • Education

    Government Medical College, Nagpur, 1986

  • Residencies

    Indiana University School of Medicine, 1997

  • Fellowships

    Memorial Sloan-Kettering Cancer Center, 2000

  • Board Certifications

    Medical Oncology, American Board of Internal Medicine

    Internal Medicine, American Board of Internal Medicine

  • Academic Title


  • Languages


The future of cancer therapy is here, and it is immunotherapy. And it arrived a lot sooner than expected!

Where I see patients (2)

    My reviews


    Overall Experience
    304 Ratings
    Explained things in a way that was easy to understand
    304 Ratings
    Did the doctor pay attention to your concerns
    302 Ratings
    Gave easy to understand instructions about taking care of health problems or concerns
    290 Ratings
    Knew the important information about your medical history
    302 Ratings
    The provider showed respect for what you had to say
    302 Ratings
    The provider spent enough time with me
    299 Ratings
    Decorative Caduceus

    Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patient...

    -Defined as the proportion of ctDNA-positive participants having a ctDNA-negative test at Cycle 3 Day 1


    Decorative Caduceus

    Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma

    The investigators will identify the genes predictive of response to anti-PD-1 therapy by testing for significant associations across expression rates of each gene and response/resistance, within a hurdle-Gaussian mixed-effect fram...


    Decorative Caduceus

    A Study of SEA-CD40 Given With Other Drugs in Cancers

    The proportion of participants who achieve a confirmed complete response (CR) or partial (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by the investigator.


    Decorative Caduceus

    Study of PF-07265807 in Participants With Metastatic Solid Tumors.

    DLTs will be evaluated during the first cycle (day 21) or two cycles (day 42). The number of DLTs will be used to determine the maximum tolerated dose (MTD)


    Decorative Caduceus

    Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malig...